Myostatin (Mstn) is postulated to be a key determinant of muscle loss and
cachexia in
cancer. However, no experimental evidence supports a role for Mstn in
cancer, particularly in regulating the survival and growth of
cancer cells. In this study, we showed that the expression of Mstn was significantly increased in different
tumor tissues and human
cancer cells. Mstn knockdown inhibited the proliferation of
cancer cells. A knockout (KO) of Mstn created by clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated
protein (Cas) 9 (CRISPR/Cas9) induced mitochondria-dependent apoptosis in HeLa cells. Furthermore, KO of Mstn reduced the
lipid content. Molecular analyses demonstrated that the expression levels of
fatty acid oxidation-related genes were upregulated and then increased rate of
fatty acid oxidation. Mstn deficiency-induced apoptosis took place along with generation of
reactive oxygen species (ROS) and elevated
fatty acid oxidation, which may play a role in triggering mitochondrial membrane depolarization, the release of
cytochrome c (Cyt-c), and
caspase activation. Importantly, apoptosis induced by Mstn KO was partially rescued by
antioxidants and
etomoxir, thereby suggesting that the increased level of ROS was functionally involved in mediating apoptosis. Overall, our findings demonstrate a novel function of Mstn in regulating mitochondrial metabolism and apoptosis within
cancer cells. Hence, inhibiting the production and function of Mstn may be an effective therapeutic intervention during
cancer progression and muscle loss in
cachexia.